Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC cut its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 38.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 536 shares of the medical research company’s stock after selling 336 shares during the period. Nisa Investment Advisors LLC’s holdings in Bio-Rad Laboratories were worth $176,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of BIO. Van ECK Associates Corp lifted its stake in Bio-Rad Laboratories by 97.8% during the third quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company’s stock worth $436,861,000 after purchasing an additional 644,530 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Bio-Rad Laboratories during the third quarter worth approximately $83,681,000. Wedge Capital Management L L P NC purchased a new stake in shares of Bio-Rad Laboratories during the 4th quarter worth approximately $28,740,000. Mawer Investment Management Ltd. boosted its holdings in shares of Bio-Rad Laboratories by 63.0% in the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock valued at $72,900,000 after buying an additional 84,237 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Bio-Rad Laboratories by 38.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 86,782 shares of the medical research company’s stock valued at $29,036,000 after buying an additional 24,052 shares during the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Trading Up 0.6 %

Bio-Rad Laboratories stock opened at $358.06 on Friday. The stock has a market cap of $10.03 billion, a PE ratio of -13.10 and a beta of 0.90. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The stock has a 50-day moving average price of $339.69 and a 200 day moving average price of $334.63. Bio-Rad Laboratories, Inc. has a 52 week low of $262.12 and a 52 week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.85. The business had revenue of $649.70 million during the quarter, compared to analyst estimates of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The company’s revenue was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.33 earnings per share. Equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.33 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on BIO shares. Royal Bank of Canada reissued an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Citigroup lifted their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $394.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.